Introduction
Smooth muscle cell (SMG)1 proliferation plays a major role in the vascular reparative response after mechanical injury. There is evidence that a variety of factors regulate this SMC growth including angiotensin-Il (1, 2), basic fibroblast growth factor 1 . Abbreviations used in this paper: bFGF, basic fibroblast growth factor; CM, conditioned media; MLE, mink lung epithelial; SFM, serumfree medium; SHR, spontaneously hypertensive rats; SMC, smooth muscle cell.
(bFGF) (3), platelet-derived growth factor (PDGF) (4, 5) , and transforming growth factor-(il (TGF-,B1) (6) . TGF-,B1 is a 25-kD growth factor released during acute phases of injury by degranulating platelets (7) and secreted during chronic phases oflesion development by SMCs (6) and activated macrophages (8) . Majesky et al. (6) demonstrated that TGF-f3l mRNA levels were elevated within 6 h of balloon embolectomy catheter-induced injury of rat carotid artery, and remained elevated for at least 2 wk. Immunohistochemical studies of vessels 2 wk after injury revealed that a large majority of intimal cells expressed TGF-#3I protein in an intracellular pattern consistent with active synthesis. Furthermore, infusion of recombinant TGF-031 into rats for 48 h, 2 wk after carotid artery injury, increased [3H]thymidine labeling indices of intimal cells by fourfold. These data strongly suggest that TGF-,B is present, both acutely and chronically, and may influence growth of SMC at sites of vascular injury.
Our understanding of the role of TGF-#3 in myointimal lesion formation after injury has been confounded by in vitro observations that TGF-,B can both inhibit as well as stimulate growth of cultured SMC. Several studies (7, 9, 10) , including one from this laboratory (11) , have shown that TGF-f is a potent inhibitor of growth factor-or serum-induced proliferation. In contrast, other investigators have found that TGF-,B stimulated SMC proliferation. Majack et al. (12) showed that TGF-f3 stimulated growth ofpostconfluent rat SMC and inhibited growth ofsubconfluent cells. Battegay et al. (13) found that TGF-f stimulated growth of cultured human SMC in a bimodal, concentration dependent manner. Both Majack et Results of recent studies have suggested that TGF-p may also have delayed effects on SMC growth that are not mediated solely by PDGF-AA production. For example, we found that angiotensin-TI (Ang-II) enhanced growth responses of SMC derived from spontaneously hypertensive rats (SHR) to epidermal growth factor (EGF), bFGF, and PDGF-BB and that these effects were delayed and dependent on autocrine production of TGF-f (14) . The effect of Ang-TI on growth responses to PDGF-BB are unlikely to be mediated via autocrine production of PDGF-AA since PDGF a receptors, the only known effectors of PDGF-AA actions, should have been fully activated by the saturating concentrations of PDGF-BB used in (15) showed that TGF-i3 alone had no effect on [3H]thymidine incorporation. However, similar to our observations, cotreatment with TGF-,B and PDGF-BB resulted in a growth effect which was 10- 
Methods
Smooth muscle cell culture. SMCs were isolated from aorta ofspontaneously hypertensive or Sprague-Dawley rats by enzymatic digestion as previously described (16) . The cells were cultured in medium containing a 1:1 formulation of Dulbecco's modified Eagle's Medium (DME; GIBCO BRL, Gaithersburg, MD) and Ham's F12 medium (GIBCO BRL) supplemented with 10% fetal bovine serum (FBS, Hyclone Laboratories, Logan, UT), L-glutamine (0.68 mM; Sigma Chemical Co., St. Louis, MO), penicillin (100 U/ml), and streptomycin (100 sg/ml). Cells were harvested for passaging at subconfluence with a trypsin-EDTA (0.05% trypsin, 0.02% EDTA, GIBCO BRL) solution. Cell cultures were incubated at 370C in a humidified atmosphere of 5% COJ 95% air. SMC identity and the purity ofcultures was verified by immunocytochemical analysis using antibodies specific for smooth muscle a-actin (17 SMC derived from SHR were grown to confluence and growth arrested in SFM. 4 as previously reported in SMC derived from Sprague-Dawley rats (12) or humans (13), PDGF-AA levels were measured in conditioned media from TGF-fl-treated and vehicle-treated SMC using a radioreceptor competition assay. Results demonstrated an eightfold increase in PDGF concentration in conditioned media (CM) 24 h after TGF-,3 as compared with vehicle treatment (Fig. 2) . PDGF-AA levels remained elevated for at least 48 h (Fig. 2) . Despite increased levels ofPDGF-AA in CM from TGF-i3-treated SMC (TGF CM), there was no increase in mitogenic activity for SMC in TGF CM as compared with CM from vehicle treated SMC (Cnt CM) (data not shown). Human recombinant PDGF-AA also stimulated only modest increases in [3H]thymidine incorporation and required concentrations far in excess of that in TGF CM (Fig. 3) . Results indicate that although TGF-3 stimulated production of PDGF-AA, these cells responded weakly to either endogenous or exogenous PDGF-AA. In contrast to effects on SHR-derived SMC, PDGF-AA is a potent mitogen for 3T3 fibroblasts which express abundant PDGF-a receptors (20) . TGF CM had increased mitogenic activity for 3T3 cells compared to Cnt CM that was partially inhibited by a monoclonal antibody (designated pfa4) that has previously been shown to neutralize rat PDGF-AA (21) (Fig. 4) . (Fig. 6 ). This effect was transient, however, in that TGF-,3 had no effect on EGF-, bFGF-, or PDGF-BB-induced [3H]-thymidine incorporation measured at 23-24 h (Fig. 6 ) or 0-24 h (Fig. 7) . Taken together, these data show that TGF-,# (100 pM) delayed EGF-, bFGF-, or PDGF-BB-induced entry into S phase but did not have an overall inhibitory effect on growth responses of SMC during the initial 24 h after treatment.
TGF-f3 induced a delayed, synergistic increase in growth responses ofSMC to EGF, bFGF, or PDGF-BB. Subsequent studies examined the effects of TGF-# on growth responses to EGF, bFGF, or PDGF-BB at later time points. Results demon- Time of H-thymidine pulse (h) Figure 6 . Effects of TGF-#I on acute growth responses of SMC to EGF, bFGF, or PDGF-BB. SMC derived from SHR were grown to confluence and growth arrested in SFM. 4 strated that co-treatment with TGF-j (100 pM) markedly increased EGF-, bFGF-, or PDGF-BB-induced growth responses measured from 48 to 72 h after treatment (Fig. 7) (Fig. 1 1) .
TGF-f3-enhanced growth responses to EGF in SMC primary lines which are unresponsive to exogenous PDGF-AA. We have identified a number of SMC primary lines derived from Sprague-Dawley rats that do not express PDGF a receptors and in which PDGF-AA elicits no measurable growth response (22) . These cells were used to further investigate whether TGF- (Fig. 12 ) as well as a significant increase in cell number (data not shown).
Discussion
TGF-# is a multifunctional growth factor which is present, both acutely and chronically, at sites of vascular injury. Effects ofendogenous TGF-# on SMC in injured vessels are unknown, although infusion of TGF-13 2 wk after vascular injury has been shown to promote SMC mitogenesis (6). Studies to date have shown that TGF-(3 stimulates modest increases in [3H]-thymidine incorporation of cultured SMC which is largely dependent on autocrine production of PDGF-AA (12, 13). Results ofthe present studies extend these earlier findings by demonstrating that higher concentrations of TGF-(3 also have pronounced, delayed effects on SMC growth. TGF-(3 (100 pM)-induced an average 24-(range 3-49) fold increase in [3H]thymidine incorporation when measured 48-72 h after treatment. This effect on SMC growth is much larger than observed in prior studies (12, 13). Additionally, TGF-(3 stimulated a marked delayed growth response to EGF, bFGF, or PDGF-BB in SHR-derived SMC and to EGF in Sprague-Dawley-derived SMC. These data are consistent with earlier studies demonstrating that TGF-# enhanced growth responses to EGF in bovine SMC (7), to bFGF or PDGF in rat SMC (12) and to PDGF-BB in rabbit SMC (15) . Similarly (25, 26) , but these effects have not been directly linked to SMC growth. TGF-3 has also been shown to regulate levels of extracellular matrix degradation by reducing the synthesis of enzymes involved in matrix proteolysis and increasing levels of proteolytic inhibitors (e.g., plasminogen activator inhibitor-l) (27) .
Results of the present studies add to the growing evidence that TGF-f3 stimulates SMC growth in vitro (12, 13), as well as in vivo (6) . There is, however, extensive evidence that TGF-fl can also inhibit growth ofcultured SMC (7, 9, 10 (31) demonstrated that confluent, growth arrested SMC expressed lower levels of 65 kD (now referred to as type I receptors), and higher levels of 280 kD (type III receptors) binding proteins relative to proliferating, subconfluent SMC. Levels of 85-kD (type II receptors) binding protein expression were similar in both groups. TGF-,B inhibited growth of rat SMC at subconfluent densities but potentiated growth of SMC at confluent densities suggesting that these effects were mediated by differential TGF-f3-binding protein expression. Taken together, these studies suggest that TGF-,B receptor expression could play a role in determining growth responses of cultured cells to TGF-3 and that this will be an important area of research for further understanding of TGF-# effects on SMC growth.
In the present studies, TGF-,B delayed EGF-, bFGF-, or PDGF-BB-induced entry of SHR-derived SMC into S phase. (33) They showed that TGF-(i treated MLE cells failed to stably assemble cyclin E-Cdk2 complexes or accumulate cyclin E-associated kinase activity. In summary, these studies provide further data regarding the effects of TGF-,3 on SMC growth. TGF-3 (100 pM) elicited marked, delayed growth responses, both alone and in combination with EGF, bFGF or PDGF-BB. TGF-fl enhanced SHRderived SMC production of PDGF-AA which partially mediated TGF-(3-induced growth. However, TGF-(3 markedly enhanced growth responses to EGF, bFGF, or PDGF-BB through mechanisms that were largely independent of PDGF-AA. Further studies will be required to identify the mechanisms whereby prolonged treatment with TGF-,3 enhances SMC growth resposiveness in cultured SMC and to determine whether similar effects occur in vivo.
